|
|
Post by goyocafe on Aug 4, 2021 22:31:04 GMT -5
TFF is still a clinical stage development company. Maybe NRX decided to abandoned them in favor of MNKD’s FDA approved Technosphere. Did Jonathan Javitt take over as CEO of NRXP last fall which allowed him to influence the choice of dry powder technologies in the direction of Mannkind? |
|
|
|
Post by goyocafe on Aug 5, 2021 4:26:43 GMT -5
Contemplating the possibilities, IF Mannkind can pull off a winning formulation, it will not only be NRXP that will have a successful partnership, but I suspect Relief Therapeutics will have a similar interest in this formulation for the market segment for which they retained rights and control.
|
|
|
|
Post by Clement on Aug 5, 2021 7:33:39 GMT -5
TFF is still a clinical stage development company. Maybe NRX decided to abandoned them in favor of MNKD’s FDA approved Technosphere. Yes, I think so too. That news article was on Mar 9, 2021. Almost 5 months later, we have the MNKD/NRXP agreement. Perhaps 3 months is long enough for TFF to try to formulate and fail. Then 2 months to make the agreement with MNKD. I'm speculating that NXRP is being very aggressive about finding a better inhalation delivery. |
|
|
|
Post by goyocafe on Aug 7, 2021 5:01:56 GMT -5
So if the possibility of formulating a compound warrants a press release, wouldn’t it be logical that if and when such a formulation is achieved that a press release would be issued for achieving that milestone as well, if not more so? MNKD-201, MNKD-301, and MNKD-701 have been in “formulation “ in the pipeline (according to the website) for months and we’ve heard nothing about them. Should we not expect to hear when these compounds are successfully formulated. This seems like a significant milestone for any compound in the pipeline. Will we hear if or when they successfully formulate Zyesami (Aviptadil)? I think the pipeline webpage needs a good dusting up.
|
|
|
|
Post by lakon on Aug 7, 2021 9:26:13 GMT -5
Wait — there's more! FTA:
"NRx Pharmaceuticals has entered a memorandum of understanding (MoU) with the Government of Israel to licence exclusive global development, manufacturing and commercialisation rights to a Covid-19 vaccine, BriLife."
"Developed by the Israel Institute for Biological Research (IIBR), BriLife is based on a vaccine platform previously approved by the US Food and Drug Administration (FDA)."
"NRx chairman and CEO Jonathan Javitt along with the company’s director Chaim Hurvitz, who chairs an Israeli private equity group, CH Health, will lead the development initiative."
"Hurvitz said: “As the first generation Covid vaccines are increasingly challenged by rapid mutation of the coronavirus, we aim to develop a vaccine that can rapidly scale at low cost to serve the needs of both the developed and the developing world.”"
"As BriLife is a self-propagating, live-virus vaccine, NRx expects that it can be quickly and cost-effectively scaled up and produced in industrial settings. Initially, the vaccine will be administered via standard injection."
After initial use, could the end goal be an inhaled Technosphere vaccine? Now wouldn't that make Al Mann [RIP] smile?
|
|
|
|
Post by goyocafe on Aug 7, 2021 9:41:13 GMT -5
Wait — there's more! FTA:
"NRx Pharmaceuticals has entered a memorandum of understanding (MoU) with the Government of Israel to licence exclusive global development, manufacturing and commercialisation rights to a Covid-19 vaccine, BriLife."
"Developed by the Israel Institute for Biological Research (IIBR), BriLife is based on a vaccine platform previously approved by the US Food and Drug Administration (FDA)."
"NRx chairman and CEO Jonathan Javitt along with the company’s director Chaim Hurvitz, who chairs an Israeli private equity group, CH Health, will lead the development initiative."
"Hurvitz said: “As the first generation Covid vaccines are increasingly challenged by rapid mutation of the coronavirus, we aim to develop a vaccine that can rapidly scale at low cost to serve the needs of both the developed and the developing world.”"
"As BriLife is a self-propagating, live-virus vaccine, NRx expects that it can be quickly and cost-effectively scaled up and produced in industrial settings. Initially, the vaccine will be administered via standard injection."
After initial use, could the end goal be an inhaled Technosphere vaccine? Now wouldn't that make Al Mann [RIP] smile?
Can live virus vaccine survive once loaded on Technosphere.? Perhaps inhaled live virus will require to be nebulized? Guessing. |
|
|
|
Post by hellodolly on Aug 7, 2021 14:46:10 GMT -5
Wait — there's more! FTA:
"NRx Pharmaceuticals has entered a memorandum of understanding (MoU) with the Government of Israel to licence exclusive global development, manufacturing and commercialisation rights to a Covid-19 vaccine, BriLife."
"Developed by the Israel Institute for Biological Research (IIBR), BriLife is based on a vaccine platform previously approved by the US Food and Drug Administration (FDA)."
"NRx chairman and CEO Jonathan Javitt along with the company’s director Chaim Hurvitz, who chairs an Israeli private equity group, CH Health, will lead the development initiative."
"Hurvitz said: “As the first generation Covid vaccines are increasingly challenged by rapid mutation of the coronavirus, we aim to develop a vaccine that can rapidly scale at low cost to serve the needs of both the developed and the developing world.”"
"As BriLife is a self-propagating, live-virus vaccine, NRx expects that it can be quickly and cost-effectively scaled up and produced in industrial settings. Initially, the vaccine will be administered via standard injection."
After initial use, could the end goal be an inhaled Technosphere vaccine? Now wouldn't that make Al Mann [RIP] smile?
“This linkage between the clinical effect of aviptadil on survival and recovery and a measurable biologic change in cytokine levels provides a basis for seeking a biomarker-based regulatory path as envisioned by the 21st Century Cures Act.” The company submitted the data from the trial to the US Food and Drug Administration (FDA) to support its Emergency Use Authorization (EUA) application for Zyesami to treat critically ill Covid-19 patients. Furthermore, NRx is planning to submit a biomarker letter of intent to the FDA based on these Phase IIb/III results. The latest development comes after NRx entered a memorandum of understanding (MoU) with the Government of Israel to license exclusive global development, manufacturing and commercialisation rights to a Covid-19 vaccine, BriLife. |
|
|
|
Post by lennymnkd on Aug 7, 2021 15:07:27 GMT -5
Live virus/ platform… ?
|
|
|
|
Post by boca1girl on Aug 7, 2021 15:24:46 GMT -5
Just curious, is anyone here buying NRXP since the partnership was announced?
|
|
|
|
Post by mymann on Aug 7, 2021 15:36:21 GMT -5
I purchased it Thursday @$14.
|
|
|
|
Post by goyocafe on Aug 7, 2021 15:38:41 GMT -5
Just curious, is anyone here buying NRXP since the partnership was announced? A bit, but immediately went underwater, a very familiar sensation. |
|
|
|
Post by uvula on Aug 7, 2021 20:16:29 GMT -5
What the hell is a "self-propagating, live-virus vaccine"?
|
|
|
|
Post by peppy on Aug 7, 2021 20:49:58 GMT -5
Wait — there's more! FTA:
"NRx Pharmaceuticals has entered a memorandum of understanding (MoU) with the Government of Israel to licence exclusive global development, manufacturing and commercialisation rights to a Covid-19 vaccine, BriLife."
"Developed by the Israel Institute for Biological Research (IIBR), BriLife is based on a vaccine platform previously approved by the US Food and Drug Administration (FDA)."
"NRx chairman and CEO Jonathan Javitt along with the company’s director Chaim Hurvitz, who chairs an Israeli private equity group, CH Health, will lead the development initiative."
"Hurvitz said: “As the first generation Covid vaccines are increasingly challenged by rapid mutation of the coronavirus, we aim to develop a vaccine that can rapidly scale at low cost to serve the needs of both the developed and the developing world.”"
"As BriLife is a self-propagating, live-virus vaccine, NRx expects that it can be quickly and cost-effectively scaled up and produced in industrial settings. Initially, the vaccine will be administered via standard injection."
After initial use, could the end goal be an inhaled Technosphere vaccine? Now wouldn't that make Al Mann [RIP] smile?
“This linkage between the clinical effect of aviptadil on survival and recovery and a measurable biologic change in cytokine levels provides a basis for seeking a biomarker-based regulatory path as envisioned by the 21st Century Cures Act.” The company submitted the data from the trial to the US Food and Drug Administration (FDA) to support its Emergency Use Authorization (EUA) application for Zyesami to treat critically ill Covid-19 patients. Furthermore, NRx is planning to submit a biomarker letter of intent to the FDA based on these Phase IIb/III results. The latest development comes after NRx entered a memorandum of understanding (MoU) with the Government of Israel to license exclusive global development, manufacturing and commercialisation rights to a Covid-19 vaccine, BriLife. wow Lakon, what a find. let's go..... WTH? Brilife. Israel isn't stupid, they seem to like their people more. BriLife (IIBR-100) Vaccine Description The Brilife (IIBR-100) vaccine candidate contains a recombinant vesicular stomatitis virus (VSV), an animal virus that does not cause disease in humans. The spike protein was replaced with that of SARS-CoV-2 that “results in rapid and potent induction of neutralizing antibodies against the SARS-CoV-2 coronavirus.” Brilife (VSV ΔG) is a vector-based vaccine that takes VSV and genetically engineers to express the spike protein of the SARS-CoV-2 beta coronavirus on its envelope. The human body recognizes the spike protein expressed on the envelope and begins to develop an immunological response. In its collaboration with NRx, announced on July 12, 2021, the Israel Institute for Biological Research (IIBR) will provide technical assistance while receiving customary royalty and milestone payments for its intellectual property. NRx has further committed to supplying all required doses of the vaccine for the population of Israel. The initiative will be led by NRx Chairman and CEO Jonathan Javitt, together with NRx Director Chaim Hurvitz, who chairs CH Health, an Israeli Private Equity group. www.precisionvaccinations.com/vaccines/brilife-vaccine |
|
|
|
Post by peppy on Aug 7, 2021 22:25:57 GMT -5
Wait — there's more! FTA:
"NRx Pharmaceuticals has entered a memorandum of understanding (MoU) with the Government of Israel to licence exclusive global development, manufacturing and commercialisation rights to a Covid-19 vaccine, BriLife."
"Developed by the Israel Institute for Biological Research (IIBR), BriLife is based on a vaccine platform previously approved by the US Food and Drug Administration (FDA)."
"NRx chairman and CEO Jonathan Javitt along with the company’s director Chaim Hurvitz, who chairs an Israeli private equity group, CH Health, will lead the development initiative."
"Hurvitz said: “As the first generation Covid vaccines are increasingly challenged by rapid mutation of the coronavirus, we aim to develop a vaccine that can rapidly scale at low cost to serve the needs of both the developed and the developing world.”"
"As BriLife is a self-propagating, live-virus vaccine, NRx expects that it can be quickly and cost-effectively scaled up and produced in industrial settings. Initially, the vaccine will be administered via standard injection."
After initial use, could the end goal be an inhaled Technosphere vaccine? Now wouldn't that make Al Mann [RIP] smile?
“This linkage between the clinical effect of aviptadil on survival and recovery and a measurable biologic change in cytokine levels provides a basis for seeking a biomarker-based regulatory path as envisioned by the 21st Century Cures Act.” The company submitted the data from the trial to the US Food and Drug Administration (FDA) to support its Emergency Use Authorization (EUA) application for Zyesami to treat critically ill Covid-19 patients. Furthermore, NRx is planning to submit a biomarker letter of intent to the FDA based on these Phase IIb/III results. The latest development comes after NRx entered a memorandum of understanding (MoU) with the Government of Israel to license exclusive global development, manufacturing and commercialisation rights to a Covid-19 vaccine, BriLife. Dolly, for Israel a vaccine, aviptadil is a therapeutic.  NRx is going to be busy. Do I have this correct? NRX pictured, the BOTS, all in a row.  |
|
|
|
Post by veritasfiliatemporis on Aug 8, 2021 2:28:20 GMT -5
Just curious, is anyone here buying NRXP since the partnership was announced? 690 at 13.3 Why not... waiting to hear the pop... |
|
